Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pulike Biological Engineering had a gross margin of 54.89% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pulike Biological Engineering Gross Margin % Related Terms
Pulike Biological Engineering Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603566 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Pulike Biological Engineering's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulike Biological Engineering Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pulike Biological Engineering's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pulike Biological Engineering's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pulike Biological Engineering (SHSE:603566) has a Gross Margin % of 54.89% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Pulike Biological Engineering and its competitors. This is 14% below median its historical median of 63.48. Over the past decade, Pulike Biological Engineering's Gross Margin % has ranged from 58.74 to 71.31. According to the industry distribution chart, Pulike Biological Engineering ranks #380 out of 733 companies in the Biotechnology industry, placing it in the top 51.8%.
Is Pulike Biological Engineering's Gross Margin % too high?
Pulike Biological Engineering's current Gross Margin % of 54.89% is 14% below median its 10-year median of 63.48. Over the past 10 years, this metric has ranged from a low of 58.74 to a high of 71.31. The Biotechnology industry median Gross Margin % is 60.91. Pulike Biological Engineering's value of 54.89% is 9.9% below this industry median. Based on the distribution chart, Pulike Biological Engineering ranks #380 out of 733 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pulike Biological Engineering has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pulike Biological Engineering's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pulike Biological Engineering ranks #380 out of 733 companies for Gross Margin %. This places Pulike Biological Engineering in the lower half of its industry. The industry median Gross Margin % is 60.91. Pulike Biological Engineering's value of 54.89% is 9.9% below this benchmark. Historically, Pulike Biological Engineering's own Gross Margin % has ranged from 58.74 to 71.31 over the past decade. While the company's 10-year median is 63.48 vs. the industry median of 60.91, Pulike Biological Engineering has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulike Biological Engineering's current Gross Margin % of 54.89% is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Pulike Biological Engineering and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulike Biological Engineering's current Gross Margin % is 54.89%, which is 14% below median its own 10-year median of 63.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulike Biological Engineering stock overvalued right now?
Based on GuruFocus' analysis, Pulike Biological Engineering (SHSE:603566) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.30, compared to a current price of ¥10.31 — trading 27.9% below its estimated fair value. The current Gross Margin % is 54.89%, which is 14% below median its 10-year median of 63.48 and 9.9% below the Biotechnology industry median of 60.91. Pulike Biological Engineering's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Pulike Biological Engineering (SHSE:603566), the current Gross Margin % is 54.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulike Biological Engineering (SHSE:603566) Overvalued in 2026?
Based on GuruFocus' analysis, Pulike Biological Engineering stock appears to be undervalued.
The current stock price of ¥10.31 is trading 27.9% below its estimated GF Value™ of ¥14.30.
GuruFocus considers Pulike Biological Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:603566:
Gross Margin %: 54.89% (14% below median its 10-year median of 63.48)
GF Value™: ¥14.30 vs. price of ¥10.31 (27.9% below fair value)
Industry Position: 9.9% below the Biotechnology median (#380 of 733)
No single metric tells the full story. See the SHSE:603566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulike Biological Engineering Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603566 has been successfully added to your 
